60 degrees pharmaceuticals defines potential human babesiosis market size for arakoda® (tafenoquine): annual max tam, sales of $245 million; cumulative through patent expiration, $1.1 billion

New drug application intended for 2026, subject to generation of positive data from three u.s. clinical trials planned or in progress total addressable market (tam) for arakoda for human babesiosis is informed by results of a 6,000 nationwide patient survey and a quantitative research study involving 300 healthcare professionals washington, july 15, 2025 (globe newswire) -- 60 degrees pharmaceuticals, inc.  (nasdaq: sxtp; sxtpw) (“60 degrees” or the “company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced it has determined the maximum size of the commercial market for arakoda® (tafenoquine) for treatment of human babesiosis to be 380,000 patients/$245,000,000 in sales annually, with a cumulative tam of 1.17 million patients/$1.1 billion through patent expiration in 2035. human babesiosis is a serious and debilitating emerging tick-borne illness often found as a co-infection in patients with lyme disease.
SXTP Ratings Summary
SXTP Quant Ranking